The $10B TAVR Market Grew. Why Are Most Patients Still Untreated?

After decades of device-delivery progress, the next era of TAVR must be judged by valve design, physiologic blood flow, and clinical outcomes. With DurAVR® THV, Anteris is bringing a pharma-style disease-management mindset to a category long defined by engineering. MINNEAPOLIS, July 13,...